VaxLiant, a company that offers a portfolio of customizable adjuvants designed to modernize how vaccines deliver antigens to prevent disease, is one of the newest members of the life science industry in Nebraska.
Formed earlier this month as a joint venture of Benchmark Biolabs of Lincoln and AgriLabs of St. Joseph, Mo., the company is headquartered at Benchmark's facilities in Lincoln but will tap into the experience of employees from both parent companies.
The company's unique antigen-delivery formulations can be used to improve immune response and deliver novel technologies that will be valuable to scientists seeking to contain highly contagious transboundary diseases. VaxLiant also can help vaccine companies enhance current vaccines and bring vaccines to the market faster and at a lower cost, thereby enabling them to meet specific needs of veterinarians and farmers.
"How our products deliver antigens is remarkable and truly unlike what is commonplace today," said Dr. Tim Miller, VaxLiant co-founder and also president and CEO of Benchmark Biolabs.
"Just as valuable is our team of people who have a track record of helping companies bring vaccines to market in a timely fashion, and who recognize the need for extraordinary delivery and adjuvant support for new technologies in the vaccine-development process," Miller added.
Founded in 1986, Benchmark Biolabs streamlines the development process from research to commercialization. Benchmark scientists have received more than 60 patents and are responsible for dozens of USDA- and FDA-approved products — including three first-in-the-world products. In addition to the company's state-of-the-art laboratory facilities, Benchmark has managed three USDA-licensed vaccine production facilities at its campus on West Industrial Lake Drive in Lincoln. AgriLabs has been a leader in commercializing vaccines, nutritionals and other animal-health products for more than 25 years.